Sandoz Accuses Eli Lilly Of Inequitable Conduct

Law360, New York (October 12, 2007, 12:00 AM EDT) -- Generic pharmaceutical company Sandoz Inc. is fighting back against Eli Lilly & Co. in an infringement battle over a patent for attention-deficit hyperactivity disorder treatment Strattera, denying the drug maker’s claims of infringement and asserting the patent-in-suit is invalid because of inequitable conduct.

In an answer and counterclaim filed Thursday in the U.S. District Court for the District of New Jersey, Sandoz alleged that Lilly’s patent describing methods for treating ADHD with atomoxetine is invalid because the drug maker withheld prior art from U.S. Patent and...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.